Pharmacokinetic evaluation of cefsulodin in children with and without cystic fibrosis treated for infectious diseases.
The pharmacokinetic characteristics of cefsulodin have been studied in 7 patients suffering from cystic fibrosis (CF) and compared to the findings in 6 children without CF. They were given intravenous bolus doses (3 min) of 40 mg/kg. The antibiotic concentrations were assayed by high-pressure liquid chromatography. The serum concentrations were lower in the CF group as reflected by the mean total area under the serum concentration curves of 180 vs. 309 mg h/1, and the serum concentrations after 8 hours which were below the detection limit in the CF patients compared to 4.7 mg/l in the non-CF. The patients with cystic fibrosis had a not significantly lower total body clearance (5.8 vs. 7.0 1/h). The serum half-life was slightly shorter in patients with CF (1.2 vs. 1.4 hours). Consequently, given microbes of the same MIC's, patients with CF should receive higher doses than those recommended for patients without cystic fibrosis.
D000293:Adolescent; D002441:Cefsulodin / Q000097:blood* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D007223:Infant; D007700:Kinetics; D008297:Male; D012141:Respiratory Tract Infections / Q000097:blood* / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000097:blood / Q000188:drug therapy
D002441:Cefsulodin